<DOC>
	<DOCNO>NCT01411514</DOCNO>
	<brief_summary>The management MS-patients require treatment immune-modifying immune-suppressive agent prevent new relapse progression disability . Several study evaluate effect steroid treatment clinical recovery acute relapse . An important unanswered clinical question , whether oral taper dose corticosteroid offer additional advantage intravenous methylprednisolone alone improve neurologic recovery well safety tolerability relapse . This study aim compare efficacy , tolerability safety taper dos oral prednisone placebo short-term high-dose i.v . methylprednisolone recovery acute relapse patient clinically isolated syndrome ( CIS ) , relapsing-remitting multiple sclerosis ( RR-MS ) primary ( PP-MS ) secondary progressive multiple sclerosis ( SP-MS ) superimpose relapse . Patients treat 25 day de-escaling dos prednisone placebo . The primary analysis test whether placebo equivalent oral prednisone taper recovery status measure EDSS change baseline 3 month baseline .</brief_summary>
	<brief_title>Oral Prednisone Taper Versus Placebo Treatment Acute Relapses Multiple Sclerosis</brief_title>
	<detailed_description>The purpose double-blind , randomise , placebo-controlled , prospective , parallel group , single centre study evaluate effect taper oral dos prednisone placebo take 25 day follow short-term high-dose i.v . methylprednisolone outcome relapse patient CIS ; RR-MS , PP-MS SP-MS superimpose relapse . The primary objective ass compare recovery status patient group 3 month baseline mean Expanded Disability Status Scale ( EDSS ) . Secondary objective assessment clinical parameter end oral treatment , 6 , 9 month baseline , MRI marker , mental cognitive status , quality life fatigue end oral treatment , 3 6 month baseline patient group . After standard treatment acute clinical relapse high dose , short term i.v . methyprednisolone patient randomise one two treatment arm . Patients allocate prednisone treat taper oral dos 25 day . The initial dose 60 mg reduce twice 20 mg , 10 5 mg. Each dose regimen take 5Â±2 day . Patients randomise placebo receive placebo treatment 25 day .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>female male age 18 80 year ; relapse form multiple sclerosis diagnose accord McDonald 's criterion , include RRMS relapse SPMS , CIS , PP ; EDSS score 0 8 ; experience acute relapse document clinical worsening least one point EDSS scale worsen least 2 point one EDSS functional system ; agree MRI already receive least one enhance MRI study procedure without major side effect ; agree adhere study procedure ; sign write informed consent form . secondary progressive MS without superimpose relapse ; primary progressive MS without superimposed relapse ; patient suffer clinical condition contraindicate steroid , particular Systemic fungal infection Severe osteoporosis Uncontrolled hypertension congestive heart failure . Existing previous history severe affective disorder ( especially previous steroid psychosis ) . Diabetes mellitus History tuberculosis Glaucoma Previous corticosteroidinduced myopathy Liver failure cirrhosis Renal insufficiency Active epilepsy Peptic ulceration Fresh intestinal anastomosis Predisposition thrombophlebitis Abscess pyogenic infection Diverticulitis Myasthenia gravis Ocular herpes simplex Hypothyroidism Recent myocardial infarction Kaposi 's sarcoma ; disease multiple sclerosis would better explain patient 's sign symptom ; woman potential childbearing without active contraceptive method ; pregnancy ( urine pregnancy test baseline visit ) breast feeding ; history affective disorder ; history attempt suicide current suicidal idea ; medical psychiatric condition compromise ability give inform consent , comply protocol , complete study ; inability , opinion principal investigator staff , comply protocol requirement duration study ; know hypersensitivity prednisone excipients study medication ; contraindication concomitant medication ; contraindication MRI contrast administration ; history drug abuse 6 month prior screen ; use steroid previous 30 day ( diseasemodifying therapy treatment MS allow ) ; treatment drug might interfere evaluation study drug study protocol ( see Section 4.2.2 ) ; likelihood require treatment study period drug permit study protocol ; participation clinical trial within 30 day prior entry study current participation another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Relapsing remittent multipse sclerosis</keyword>
	<keyword>Secondary progressive multiple sclerosis</keyword>
	<keyword>Clinically isolated syndrome</keyword>
	<keyword>Primary progressive multiple sclerosis</keyword>
</DOC>